Canaccord Genuity Maintains a 'Hold' on Genomic Health (GHDX); Raising PT and Estimates
Tweet
Share
E-mailGet Alerts GHDX Hot Sheet
Price: $63.44 --0%
Rating Summary:
3 Buy, 15 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 15 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on Genomic Health Inc. (NASDAQ: GHDX) price target raised to $31.00.
Analyst, Jeffrey Frelick, said, "GHDX reported a good Q1 that beat both our and consensus estimates, led by strong sequential growth (+9%) in Oncotype DX. Despite a solid quarter, we maintain our rating as we wait for GHDX to gain acceptance with its prostate cancer test, a significant opportunity beginning in ‘13E."
"We lowered our 2012 EPS estimate from $0.17 to $0.02 and our 2013 EPS estimate from $0.30 to $0.13, reflecting drags of $8M (’12) and $12M (’13) hitting operating expenses as a result of the new InVitae subsidiary. We raised our 2013 revenue estimate by $7.5M to $267.8M to reflect accelerating volumes."
For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on Genomic Health Inc. click here.
Shares of Genomic Health Inc. closed at $29.23 yesterday.
Analyst, Jeffrey Frelick, said, "GHDX reported a good Q1 that beat both our and consensus estimates, led by strong sequential growth (+9%) in Oncotype DX. Despite a solid quarter, we maintain our rating as we wait for GHDX to gain acceptance with its prostate cancer test, a significant opportunity beginning in ‘13E."
"We lowered our 2012 EPS estimate from $0.17 to $0.02 and our 2013 EPS estimate from $0.30 to $0.13, reflecting drags of $8M (’12) and $12M (’13) hitting operating expenses as a result of the new InVitae subsidiary. We raised our 2013 revenue estimate by $7.5M to $267.8M to reflect accelerating volumes."
For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on Genomic Health Inc. click here.
Shares of Genomic Health Inc. closed at $29.23 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Keefe, Bruyette & Woods Resumes Canadian Imperial Bank of Commerce (CM:CN) (CM) at Market Perform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
